Major drugmaker loses $27 billion in market value after failed trial
THE SO WHAT
A $27B wipeout on a single failed Phase III trial is a stark reminder of how binary late-stage biotech risk remains. For teams betting on AI in drug discovery, the opportunity is less about hype and more about shaving probability off these catastrophic endpoints in the pipeline.
READ THE SOURCE
MORE FROM THE WIRE
Deep & Emerging TechIs Optical Scale-Up Finally Approaching?
If optical starts to move inside the box — not just between racks — AI system design shifts from PCIe/NVLink constraints to photonics-aware topologies. Infra teams speccing next-gen clusters should treat optical interconnects as a 3–5 year planning question, not a science project.
Deep & Emerging TechIndia scraps import duties on some parts used to make phones and other devices until March 2029, removing 7.5% and 5% levies, in a move that might help Apple
India cutting 5–7.5% duties on key components through 2029 is a clear invite to deepen local assembly and upstream supply chains. Hardware operators should treat India not just as a final-assembly hub but as a medium-term base for component manufacturing and export.
Deep & Emerging TechSK Hynix’s Nasdaq listing draws more than seven times the shares on offer
A 7x oversubscribed US listing for a memory maker underlines how central DRAM and HBM are to the AI trade. For system builders, this demand backdrop means memory pricing and availability remain strategic variables — not commodities you can assume will be there.
Deep & Emerging TechNextcloud leaks 367K records — European cloud giant exposes staff and clients in major breach
A 367,000-record leak from a cloud provider via misconfiguration is a reminder that your SaaS vendors are part of your attack surface. Security teams should revisit vendor due diligence and insist on concrete evidence of config management and breach response, not just certifications.